J&J: positive study in lung cancer

(CercleFinance.com) - Johnson & Johnson announces that a phase III study showed that the combination of Rybrevant and Lazcluze offered a durable advantage over osimertinib in patients with advanced non-small cell lung cancer with EGFR mutations.


After three years' follow-up, 61% of patients on this combination were alive, compared with 53% on osimertinib.

' This chemotherapy-free combination blocks the EGFR and MET pathways while mobilizing the immune system, offering prolonged benefits', reports Dr. Shirish M. Gadgeel, Head of the Division of Hematology and Oncology.

Copyright (c) 2024 CercleFinance.com. All rights reserved.